life scienc tool diagnost
ep line fine-tun estimate
handili exceed estim stronger revenu off-set
weaker profit factor line drive beat
note narrow rais guidanc midpoint
fulli encompass sizeabl ep beat rais ep
reflect ep upsid partial off-set lower
profit expect tp stand
revenu ahead profit light medic woe ensu revenu
stronger core growth
vs estimate medic line view
stronger volum partial off-set divestitur china navihealth pharma
segment oper profit growth exceed plan
medic profit growth significantli disappoint
reflect increas cost privat label product aforement
divestitur ebitda margin fell bp bp plan
gener billion cash facilit million dividend
share may move lower expect admittedli low
meaning oper miss driven weak medic segment perform
medic oper profit expect declin lsd-msd vs
prior rise msd-hsd view share may eas said
encourag stronger pharma experi importantli
announc renew health relationship june
underscor valu provid partner continu
transit year on-going profit pressur across pharma
medic segment expos prolong challeng diversif
strategi focu call like remain medic profit trajectori
pharmaceut growth driver opioid litig portfolio optim
risk drug price acquisit miscu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
healthcar servic product compani
distribut brand gener pharmaceut well broad
varieti medic surgic product
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
compani mention price
